Abstract 2092P
Background
Breast cancer tops the list of cancer types prevalent in Algeria, with more than 14,000 new cases recorded each year, of which a significant rate appears before the age of 40. it is aggressive and requires the use of chemotherapy known to be associated with immediate and long-term toxicities, which may affect the quality of life of cancer survivors. One of the chemotherapy-related long-term toxicities among premenopausal patients is hormonal changes with ovarian failure, chemotherapy-related amenorrhoea (CRA) and early menopause witch may lead to bone loss.The objectives were to evaluate bone mineral density (BMD) and to determine potential associated factors for bone loss among young premenopausal patients after adjuvant chemotherapy.
Methods
We included premenopausal Algerian aged <45 years who had received adjuvant chemotherapy. At study entry, background demographics, cancer characteristics and menstrual history were collected; BMD was measured by DXA in trabecular and cortical sites. Factors associated with reduced BMD and fracture risk were analyzed.
Results
A total of 83 patients were evaluated.The median age at the time of diagnosis of breast cancer is 37 years old, while the age at entry into the study is 43 years old. The median BMDs for femoral neck (FN) was 1.02 g/cm2 and lumbar spine (LS) 0.95 g/cm2; 37.2% had abnormal Z-scores (defined as ≤–1) and 44.7% had osteopenia/osteoporosis of either FN or LS. On multivariate analyses, factors that were identified correlated with bone loss (low BMD) are: young age at cancer diagnosis (OR [95% CI] = 2.103 [1.091–3.181), low Vitamine D level (OR = 2.254 [1.541–4.637]), low BMI (OR = 2.56 [1.599–2.907]), longer interval since last adjuvant treatment (OR for LS: 2.217 [1.250–4.357]), and having received adjuvant tamoxifen (OR = 1.752 [1.243–3.841]).
Conclusions
This study highlights that bone loss is prevelent condition in early breast cancer survivors who are on or after chemotherapy. About 44.7% of early breast cancer survivors found to have bone loss .To prevent bone fracture; certain factors associated with this condition deserve to be detected and corrected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HCA Hospital University of Algiers Algeria.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2126P - Exercise implementation into a clinic setting with 1.660 cancer patients: Real-world data from eight years oncological exercise therapy in Cologne (OTT)
Presenter: Timo Niels
Session: Poster session 06
2127P - Long-term yoga reduces the side effects of systemic therapies and improves arm symptoms in the breast cancer patients
Presenter: Mayank Jain
Session: Poster session 06
2128P - exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
Presenter: Sara Pilotto
Session: Poster session 06
2129P - Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients
Presenter: Ying Wang, Sarah Yeo
Session: Poster session 06